Articles tagged with Pancreatic Cancer
A ketogenic diet has been shown to starve pancreatic cancer cells and enhance the effectiveness of a triple-drug therapy. The study, led by TGen, found that the diet reduced glucose levels in tumors and elevated ketone bodies, leading to increased stress on cancer cells.
A new clinical trial, named after Dr. Nate Nieto, aims to test the efficacy of a Vemurafenib and Sorafenib combination against advanced pancreatic cancer. The trial will involve about 10 patients with specific KRAS gene mutations, using liquid biopsy blood tests to identify different types of mutations.
A new study found that dual-eligible patients for Medicare and Medicaid have poorer outcomes and higher costs after cancer surgery, even in high-quality hospitals. These patients are more likely to experience complications, longer hospital stays, and lower chances of going home instead of a nursing facility.
Researchers have discovered that cancer cells carrying a common mutation accumulate large amounts of ferrous iron, which can be exploited to deliver powerful anticancer drugs. The therapeutic strategy could treat various cancers driven by KRAS mutations.
Research suggests that changes in the microbiome may play a role in both the development and progression of pancreatic cancer. A distinct gut microbial profile was observed in patients with ductal pancreatic cancer compared to those without the disease, and this signature consistently identified patients regardless of disease stage.
Researchers have identified a genetic signature of 27 microorganisms in stool samples that can predict the risk of pancreatic ductal adenocarcinoma and diagnose patients with earlier stages of the disease. This breakthrough could lead to an effective, non-invasive way to detect pancreatic cancer early.
Researchers identified a molecular signature of 27 microorganisms in stool samples that can predict pancreatic ductal adenocarcinoma risk and diagnose earlier stages. The study suggests a non-invasive, rapid, and affordable diagnostic kit could be developed to detect the disease.
Researchers have discovered a new treatment that blocks inflammation in pancreatic cancer, making it sensitive to chemotherapy and immunotherapy. The therapy more than doubled survival rates in mice with pancreatic cancer, providing promising results for future human trials.
A team of researchers from Charité – Universitätsmedizin Berlin have elucidated the process underlying drug resistance in aggressive pancreatic cancer. They found that inhibition of the RUNX1 protein limits cancer growth and may lead to effective treatment options.
A new study suggests that common blood pressure medications can prolong survival for pancreatic cancer patients. The study found that patients who took ARB-type therapies and ACE inhibitors had a lower risk of mortality compared to those who did not.
Researchers discovered that cancer cells use a combination of proteins to repel T cells and protect themselves from the immune system. By disabling this protection, scientists were able to allow T cells to infiltrate and attack pancreatic tumors, leading to shrinkage or disappearance.
A Toronto study found that certain probiotic bacteria can alter the function of immune cells and spur cancer growth in pancreatic cancer. Deletion or inhibition of a key protein enabled better treatment sensitivity and more inflammatory T cells, while activation thwarted these effects.
Researchers at the University of Illinois Chicago have developed a compound that may offer hope for pancreatic cancer treatment. The experimental compound, XP-524, has been shown to more than double the average survival time for mice with pancreatic cancer when combined with immunotherapy.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers have designed a nanoparticle system that can deliver fluorescent dyes to diagnose and treat pancreatic cancer tumors. The system overcomes the challenge of reaching cells deep within dense tumor masses, enabling detailed images of tumor structures and potentially targeted therapies.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
Researchers used optical imaging to study the metabolic interactions between pancreatic cancer cells and surrounding non-cancer cells. They found that cancer cells can hijack the metabolic activity of these non-cancer cells to fuel tumor growth. This discovery could lead to new therapies targeting the tumor microenvironment.
A new review suggests that moderate coffee consumption can stimulate digestive processes and help movement through the colon. The study also found a possible association between coffee consumption and reduced risk of gallstones and certain liver diseases. However, further research is needed to confirm these findings.
Jonsson Comprehensive Cancer Center researchers have identified signaling mechanisms in pancreatic cancer cells that could be targeted for treatment. By inhibiting a specific protein, cancer cells' DNA can become damaged and induce programmed cell death, providing a potential new strategy for treating this aggressive form of cancer.
Researchers have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy, reducing tumor size by about half and improving survival rates. The combination of ATI-450 with chemotherapy also mitigates side effects, including nausea and fatigue, in mice with human pancreatic cancer cells.
A study published in eLife reveals that a small signalling protein called ARL4C is overexpressed in pancreatic cancer patients, facilitating their aggressive behavior. By inhibiting ARL4C, researchers have shown promise in reducing the spread of pancreatic cancer cells, opening up new therapeutic avenues.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
Researchers have identified two new symptoms – thirst and dark urine – associated with pancreatic cancer, which could help doctors diagnose the disease earlier. The study found 23 symptoms linked to pancreatic cancer, with patients often experiencing non-specific symptoms up to a year before diagnosis.
Researchers discovered that pancreatic injury leads to the formation of new cell types that can give rise to cancerous mutations. The study provides a valuable resource for understanding the processes behind pancreatic cancer and potential therapeutic targets.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
A new TGen study is exploring the use of checkpoint inhibitors to treat pancreatic cancer by modulating the tumor microenvironment and rendering it vulnerable to immunotherapies. The study, funded with a $1 million grant, aims to overcome the resistance of pancreatic cancer to treatments, including immune therapies.
The MUSC Hollings Cancer Center researchers are exploring the role of macroenvironment in pancreatic cancer-induced cachexia to address this debilitating condition. The team aims to provide new biological insight, which will be coordinated by four cores within the program project grant.
A study found that plasma cell-free miR-181c and tissue expression of miR-21, -210 accurately diagnose pancreatic adenocarcinoma (PA) with high accuracy. Further research is needed to validate its utility as a biomarker for PA diagnosis and monitoring.
Researchers have developed a new approach to deliver therapeutic nucleic acids using nanoparticles coated with antibodies. This system targets cancer cells while sparing normal cells, showing improved efficacy and reduced toxicity compared to previous methods.
Researchers used Caenorhabditis elegans to detect very-early-stage pancreatic cancer, achieving a reported sensitivity of 95.8%. The method showed promise for use in detecting patients with early PDAC, but the underlying mechanisms need further clarification.
A simulated screening process for a pancreatic cancer clinical trial showed that Black patients were significantly more likely than white patients to be excluded from trials. The study found that nutrition and infectious disease criteria disproportionately excluded Black patients, while a history of prior cancer treatment excluded more...
A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.
Researchers at Purdue University have successfully reversed pancreatic cancer progression in a new model called the acinus, which produces digestive enzymes. The study found that reactivating the PTF1a gene in cancerous cells converted them back into normal cells, revealing a potential path to treating pancreatic cancer.
Researchers at Mount Sinai have developed a novel therapy called MS67 that effectively fights acute myeloid leukemia with mixed lineage leukemia rearrangement. The therapy degrades the WDR5 protein, which drives the proliferation of this type of leukemia and other cancers such as pancreatic cancer.
Researchers have discovered a new approach to prime the tumor environment to make chemotherapy more effective for pancreatic ductal adenocarcinoma. By reducing stiffness and density of connective tissue, cancer spread was reduced by up to 50%. The study paves the way for a clinical trial to assess the therapy approach's effectiveness.
Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Researchers at Johns Hopkins Medicine have identified promising new targets for pancreatic cancer treatment and early detection, including glycosylated proteins that could be captured in the blood for diagnosis. The study also suggests new ways to improve immune response to these tumors.
Pancreatic cells display adaptive response to repeated inflammatory episodes, reprogramming gene expression and epigenetic regulation that cooperates with mutant KRAS to promote tumor formation. Inflammation drives long-term changes in epithelial cells that select for cancer-causing mutations.
Researchers at UNSW Sydney have found the specific protein responsible for keeping cells attached to collagen, a key finding for cancer research. The discovery could lead to new directions for cancer treatment by targeting the protein tropomyosin, which is involved in forming the anchor's chain.
Researchers at MIT developed a new way to grow pancreatic organoids using synthetic gel, allowing for study of interactions between tumors and environment. The gel can also be used to grow other types of tissue, including intestinal and endometrial tissue.
A population-based cohort study in Canada identified mortality patterns for different types of neuroendocrine tumors (NETs), revealing varying risks of cancer-related and non-cancer death. The study found that small NETs can be safely monitored, while larger tumors may require more aggressive treatment.
Black, Hispanic, Indigenous and Asian Americans remain underrepresented in pancreatic cancer clinical trials, despite federal mandates. The lack of diversity hurts patients and science alike, with racial and ethnic minorities accounting for a disproportionate burden of pancreatic cancer cases.
Researchers have discovered that inhibiting the GOT1 enzyme can promote ferroptosis, a type of programmed cell death, in pancreatic cancer cells by conserving nutrients and releasing iron stores. This study provides a new potential therapeutic target for treating pancreatic cancer.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Researchers have developed an immunotherapy strategy that combines three drugs to boost the immune system against tumors. The new therapy showed promising results in mice, with pancreatic tumors shrinking or disappearing completely in about half of the animals.
Researchers at Johns Hopkins Medicine have discovered that mebendazole, an anti-parasitic drug, can prevent and slow the growth of pancreatic cancer in genetically engineered mice. The study suggests that mebendazole may act similarly to collapsing cancer cells' structure and reducing inflammation.
Researchers at University of Pennsylvania School of Medicine developed a new technology for cellular immunotherapy that targets KRAS mutations in lung, colorectal, and pancreatic cancers. The therapy uses human cells to mobilize an immune system attack on mutated KRAS tumors and shrink them.
Scientists discovered that cells from different organs are differentially susceptible to activating mutations in cancer drivers, leading to distinct outcomes. The findings highlight the importance of understanding tissue-specific genetic networks and interactions to develop precise molecular interventions.
Researchers at Queen Mary University of London have discovered that immune cells can be stimulated to assemble into special structures within pancreatic cancer, improving the efficacy of chemotherapy. The findings suggest a potential therapeutic strategy for promoting an anti-tumour immune response in patients.
The MasSpec Pen technology has been shown to accurately identify healthy and cancerous tissue in pancreatic cancer surgeries, giving patients the greatest chance of survival. The device is over 100 times faster than current gold standard diagnostic methods.
Researchers found that reducing PTHrP levels can prevent metastasis and improve survival in mice with pancreatic cancer. The study also showed promising results with anti-PTHrP antibodies targeting human pancreatic cancer cells, offering a new potential treatment approach.
The German National Academy of Sciences Leopoldina hosted a virtual symposium to discuss cancer research, particularly pancreatic cancer, and palliative care. Experts shared insights into the development of rare pancreatic tumors, mechanisms leading to metastasis formation, and resilience in palliative care.
A new study has identified a protein called pentraxin 3 (PTX3) that may be used to aid in the diagnosis of pancreatic cancer. PTX3 levels were found to be significantly higher in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer.
Researchers discovered that pancreatic cancer cells use a backup protein complex to survive when KRAS is blocked, allowing them to continue growing and dividing. This finding highlights the need for drugs that can target multiple molecules in cancer cells to improve treatment outcomes.
Researchers discovered a targeted drug, AT7519, effective in thwarting pancreatic tumors addicted to mutant KRAS gene. The study found that this CDK inhibitor selectively kills mutant KRAS-addicted cancer cells.
Researchers found that autophagy and the G2 checkpoint are interrelated processes in pancreatic cancer cells, helping them survive radiotherapy. Inhibiting the G2 checkpoint suppresses tumor growth, suggesting new tools to combat radiation-resistant PDAC cells.
A new study published in PLOS ONE demonstrates the potential of machine learning to identify high-risk patients with pancreatic cancer up to 2 years before diagnosis. The algorithm achieved high sensitivity and specificity rates, identifying 41% of patients under 60 as high risk and 72% of those diagnosed as having a detectable risk. T...
Chronic pancreatitis is a debilitating disease with poorly understood causative factors. Researchers at Osaka University identified disturbed molecular pathways and revealed underlying mechanisms that may inform effective therapy against the disease.